ArticleAntibiotics (Basel, Switzerland)2021
Evaluation of Heterocyclic Carboxamides as Potential Efflux Pump Inhibitors in
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Efflux-mediated carbapenem resistance: unveiling genetic drivers, clinical implications, and strategies for global antimicrobial stewardship.Antonie van Leeuwenhoek · 2026Review
- TXA11114: Discovery of anAntibiotics (Basel, Switzerland) · 2026Article
- Landscape of resistance to ceftolozane/tazobactam and ceftazidime/avibactam in strains of Pseudomonas aeruginosa: a genomic approach in strains without selection pressure in a tertiary-care paediatric hospital in Mexico.BMC infectious diseases · 2026Article
- Broadly Defined Antibiotic Adjuvants forThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Exploring novel amides as efflux pump inhibitors for overcoming antibiotic resistance in multidrug-resistantIranian journal of microbiology · 2025Article
- Antibiotic potentiators as a promising strategy for combating antibiotic resistance.npj antimicrobials and resistance · 2025Review
- Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins AgainstMicroorganisms · 2025Article
- Bacterial Efflux Pump Inhibitors Reduce Antibiotic Resistance.Pharmaceutics · 2024Review
- The Art of War withAntibiotics (Basel, Switzerland) · 2023Review
- Update on the Discovery of Efflux Pump Inhibitors against Critical Priority Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2023Review
- The Structures and Binding Modes of Small-Molecule Inhibitors ofAntibiotics (Basel, Switzerland) · 2022Review
- Evaluation of a Conformationally Constrained Indole Carboxamide as a Potential Efflux Pump Inhibitor in Pseudomonas aeruginosaAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to rescue the activity of antimicrobials that are no longer effective against bacterial pathogens such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.